Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on October 27, 2008, by Lexaria Corp. (Lexaria Bioscience Corp.), a Nevada corporation. The filing discloses the entry into a material definitive agreement and the creation of a direct financial obligation on the same date.
Key Financial Metrics and Transaction Details
The Company entered into a Purchase Agreement to raise CDN $900,000 through the issuance of an 18% interest-bearing Promissory Note. The transaction includes the following financial terms:
- Principal Amount: CDN $900,000
- Interest Rate: 18% per annum
- Security: The Note is secured by specified assets of the Company under a Security Agreement.
- Conversion Option: Purchasers may voluntarily convert the Note to Common Shares at $0.45 per share while the Note is outstanding.
- Warrant Issuance: Warrants were issued as consideration, calculated based on the purchase amount divided by $0.45.
- Series A Warrants: 1-year term, exercise price of US $0.45 per whole share (2 warrants required per share).
- Series B Warrants: 2-year term, exercise price of US $0.90 per whole share (2 warrants required per share).
- Mandatory Conversion: Warrants may be mandatorily converted by the Company if the Common Stock closes at 200% of the applicable exercise price for 20 consecutive trading days.
The filing text does not provide specific values for the Company's total revenue, profit, cash flow, margins, or aggregate debt levels outside of this specific transaction.
Material Changes and Debt Restructuring
A material change involves the restructuring of existing indebtedness. The Company and Purchasers agreed that all previous Loan Agreements are terminated. Any amounts previously due and owing under those agreements are replaced and superseded by the new Promissory Notes issued under this Purchase Agreement.
Outlook, Risks, and Unusual Items
The transaction was executed with three non-US persons pursuant to the exemption from registration provided by Regulation S under the United States Securities Act of 1934. The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard terms of the debt and warrant instruments.
Key Facts for Investor Verification
- Verify the specific assets pledged as collateral under the Security Agreement.
- Confirm the total amount of debt replaced by this new CDN $900,000 Note.
- Assess the dilution impact of the voluntary conversion of the Note and the exercise of Series A and Series B Warrants.
- Review the Company's ability to service the 18% interest obligation given the current market environment.